Usercentrics Surpasses €100M ARR ($117M USD) as Market Leader in Data Privacy, Paving the Way for Privacy-Led Marketing
15.10.2025 08:00:00 CEST | Business Wire | Press Release
Usercentrics today announced it surpassed €100 million in Annual Recurring Revenue (ARR), approximately $117 million USD in late August, to the tune of profitable 45% YoY growth,powered by millions of users. This milestone elevates Usercentrics into the elite “centaur” category - SaaS companies generating over €100 million in recurring revenue annually. With fewer than 200 private companies worldwide at this level, centaur status is increasingly viewed as a more meaningful benchmark than unicorn valuations, which can be inflated by high multiples on lower revenues. The milestone cements Usercentrics’ position as the leader of a new marketing era: Privacy-Led Marketing - trusted by millions of users worldwide and strengthened through strategic partnerships with global technology leaders, including Google, Amazon, and Microsoft.
Privacy Pays Off
With AI accelerating and expectations rising, the connection between privacy and trust has never been more vital and the global landscape is shifting fast: 82% of the world’s population is now covered by some form of data privacy regulation (IAPP, 2025), and people are responding. They vote with their wallets, and trust is now the most valuable currency. According to Cisco’s 2025 Data Privacy Benchmark Study, a staggering 95% of customers won’t buy from organizations that don’t protect their data. That makes privacy not just a compliance checkbox, but a foundational business imperative.
“Privacy is not just an obligation - it’s a strategic growth engine,” said Donna Dror, CEO of Usercentrics. “We're not simply ensuring compliance; we’re architecting a foundation where trust and data privacy catalyze performance.”
A Profitable Global Movement
Usercentrics processes over 7 billion consents each month across 2.3 million websites/apps and is already the global market leader in digital trust. The company continues to scale profitably and is backing its momentum with strong cash reserves and disciplined operations.
A new North American HQ in New York fortifies Usercentrics’ global presence as it accelerates the adoption of Privacy-Led Marketing in U.S. markets.
Innovation with Integrity
Building on the successful launch of its Server-Side Tagging (SST) platform, Usercentrics is evolving its offerings to help brands collect, activate, and measure consented data across websites, mobile apps, IoT devices, and AI interfaces. These innovations are engineered to deliver greater marketer control, richer insights - all while reinforcing performance and trust. Looking ahead, Usercentrics is exploring targeted M&A opportunities to strengthen its product ecosystem while continuing to deliver sustainable profitability.
About Usercentrics
Usercentrics is the global market leader in data privacy solutions, commanding the largest market share and driving profitable growth. Empowering companies worldwide, its solutions help organizations collect, manage, and measure consented user data across websites, apps, and connected platforms, enabling both compliance and Privacy-Led Marketing.
Learn more at usercentrics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251014687594/en/
Contacts
Press contact: Hannah Sinz, Sr. PR Manager, pr@usercentrics.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom